Harvest Time? Medicago And GSK Expect Summer Readout For Plant-Based COVID Vaccine

Vaccine Grown In Greenhouse Crops

 
• By Andrew McConaghie

Medicago’s vaccine has generated a strong immune responses in a Phase II trial, which could see it finally reap the benefits of its plant-based technology.

Medicago factory, North Carolina
Medicago currently only has enough capacity to supply Canada's 76 million dose order, but wants to eventually produce 1 billion doses a year. • Source: Medicago

More from Business

More from Scrip